JANX today
$11.49-$0.90 (-7.22%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $20.31
Key levels
Resistance$14.46
Resistance$13.16
Support$11.47
Support$9.87
Latest news & SEC filings
AnalystJanux Therapeutics cut to Peer Perform by Wolfe Research
AnalystUBS starts Janux Therapeutics coverage with Hold rating
AnalystPiper Sandler keeps Buy rating on Janux Therapeutics
AnalystStifel Financial keeps bullish rating on Janux Therapeutics
All JANX news →About Janux Therapeutics
Janux Therapeutics is a drug developer focused on immunotherapies for treating cancer and autoimmune disorders. It uses three in-house technology platforms to create tumor-activated T cell engagers, tumor-activated immunomodulators, and adaptive immune response modulators. Its most advanced candidates address prostate cancer and other solid tumors, while a separate program targets B-cell-driven autoimmune disease. The company also partners with larger pharmaceutical firms on additional cancer programs.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Janux Therapeutics, Inc. (JANX)
What Is the Price Target for JANX?
SEPT Low Target
$15.00
SEPT Mid Target
$26.00
SEPT High Target
$55.00
Analyst Consensus
$26.00
Is JANX a Buy or Sell Right Now?
Thesis
- •Revenue growing -5.5% YoY with STABLE trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for JANX.
Start Free Trial →Is JANX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$28.73
19
Moat Score
NONE
2/9
Piotroski Score
10.7
Altman Z-Score
What Is Smart Money Doing with JANX?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Simson Jake | director | Buy | 5,500 | - | Jun 11, 2026 |
| Hernday Natasha | director | Buy | 5,500 | - | Jun 11, 2026 |
| Kung Winston | director | Buy | 5,500 | - | Jun 11, 2026 |
| Barrett Ronald W | director | Buy | 5,500 | - | Jun 11, 2026 |
| CAPPS VICKIE L | director | Buy | 5,500 | - | Jun 11, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 5,500 | - | Jun 11, 2026 |
| DOBMEIER ERIC | director | Buy | 5,500 | - | Jun 11, 2026 |
| Doyle Janeen Noel | officer | Sale | 4,059 | $57K | Jun 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →JANX Growth Story
Revenue YoY
-5.5%
3yr Revenue CAGR
5.1%
EPS Growth YoY
-42.97%
FCF Growth YoY
-88.5%
Revenue Trend
STABLE
Dark Pool Trades for JANX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for JANX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:10 | $11.49 | 5,783 | $$66K | SELL |
| 21:00:10 | $11.49 | 5,062 | $$58K | SELL |
| 21:00:10 | $11.49 | 1,283 | $$15K | SELL |
| 21:00:10 | $11.49 | 1,669 | $$19K | SELL |
| 21:00:08 | $11.49 | 5,268 | $$61K | SELL |
5 dark pool trades shown · $$219K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for JANX
PREVIEWSEPT Investing provides real-time options flow tracking for JANX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $15 | Feb 19 | 99 | $$400 | 1 | SWEEP |
| PUT | $12.5 | Feb 19 | 99 | $$225 | 1 | SWEEP |
| PUT | $12.5 | Feb 19 | 99 | $$225 | 1 | SWEEP |
| PUT | $12.5 | Feb 19 | 99 | $$225 | 1 | SWEEP |
| PUT | $12.5 | Feb 19 | 99 | $$225 | 1 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About JANX
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for JANX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $JANX (Janux Therapeutics, Inc.) Price: $15.36 | Zone: $14.45 to $15.44 Conviction: LOW | Analyst upside: +81.2% Near resistance (88% of range) — breakout watch. No recent news — techn...
Join 3,500+ traders discussing JANX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Janux Therapeutics, Inc. (JANX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →JANX — frequently asked questions
What is JANX stock price today?
Janux Therapeutics, Inc. (JANX) is at $11.49, down 7.22% (-$0.90) at the Nov 12, 2026 close.
Why is JANX stock down today?
Nov 11, 2026: Janux Therapeutics shares closed at $12.39, up 2.82% on the day, trading between a low of $11.97 and a high of $12.77 on volume of 1,164,719. The move came as Piper Sandler repeated its Buy rating on the stock and Stifel Financial reiterated its bullish rating, though neither firm provided a new price target or additional details.
What is the JANX price target?
The average analyst price target for JANX is $26.00, ranging from $15 to $55, based on 10 analysts. Latest: Barclays maintains on Nov 6, 2026.
What do analysts rate JANX?
Analyst ratings for JANX: 2 Buy, 9 Hold, 2 Sell — consensus Hold.
Did JANX beat earnings?
JANX last reported on Nov 5, 2026: EPS -$0.34 vs -$0.47 expected — a beat of 28.2%.
Does JANX pay a dividend?
JANX does not currently pay a dividend.
What are JANX support and resistance levels?
Support: $11.47, $9.87, $7.81. Resistance: $13.16, $14.46, $15.75.
What are insiders doing with JANX?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on JANX?
Nov 12, 2026: Janux Therapeutics cut to Peer Perform by Wolfe Research · Nov 11, 2026: UBS starts Janux Therapeutics coverage with Hold rating · Nov 11, 2026: Piper Sandler keeps Buy rating on Janux Therapeutics